

Vaccines Market Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others), Route of Administration (Injection, Oral, and Other), Age Group (Pediatric and Adult), and Geography

<https://marketpublishers.com/r/VEADB772E71BEN.html>

Date: July 2025

Pages: 226

Price: US\$ 4,450.00 (Single User License)

ID: VEADB772E71BEN

Abstracts

The vaccines market size is expected to grow from US\$ 80.45 billion in 2024 to US\$ 118.94 billion by 2031; it is projected to register a CAGR of 5.7% during 2025-2031. The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives are noteworthy factors contributing to the expansion of the vaccines market size. However, the high vaccine development cost and increased time to market hinder the vaccines market growth.

Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data—a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.

The strategic value of AI was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines, enabling companies to move from viral genome sequencing to regulatory approval within a year. In 2021, Pfizer leveraged an advanced AI-driven platform, SDQ, to streamline clinical data processing. This machine learning tool reduced the time required to clean and analyze trial data from over 30 days to just 22 hours after reaching efficacy milestones, significantly enhancing operational efficiency and speed to market.

In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In March 2025, Los Alamos announced that the scientists in Los Alamos National Laboratory are combining experimental data and AI for accelerating vaccine and drug development. The RAPTER vaccine development project is leveraging AI and experimental studies to expedite traditional research methods. It aims to create a predictive tool that analyzes pathogen genetic sequences and identifies effective vaccine options for rapid outbreak responses. The team is developing this tool using AI-based knowledge extraction, mechanistic modeling, and in vitro and in vivo experiments to test promising candidates. Initially, RAPTER will focus on three pathogens: SARS-CoV-2, Ebola virus, and Burkholderia pseudomallei, the bacterium that causes melioidosis, deemed a significant biological threat.

Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses. This is expected to contribute to the growth of the vaccines market in the coming years.

Age Group -Based Insights

Based on age group, the vaccines market is segmented into pediatric and adult. The pediatric segment held the largest vaccines market share in 2024. Pediatric vaccines are immunizations given during infancy and childhood to protect against infectious diseases that pose significant risks in early life. These vaccines are typically scheduled in national immunization programs and include protection against diseases such as

diphtheria, pertussis, tetanus (DTP), polio, rotavirus, measles, mumps, rubella (MMR), hepatitis B, pneumococcal, and more. This segment continues to grow due to rising awareness about early childhood immunity, increased global coverage efforts by organizations, and strong government mandates in both developed and developing countries. The burden of vaccine-preventable diseases in infants and the long-term health and economic benefits of early immunization have led to sustained policy and funding support. Combination vaccines that reduce the number of injections (e.g., pentavalent or hexavalent) and newer additions like HPV and malaria vaccines for children have further expanded the pediatric portfolio. Advances in vaccine technology, such as thermostable and needle-free delivery systems, also support outreach in low-resource areas, thereby fueling the vaccines market growth.

The World Health Organization and UNICEF are among the primary and secondary sources referred to while preparing the vaccines market report.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global vaccines market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies - Vaccines Market

GlaxoSmithKline plc

Sanofi SA

CSL Seqirus

Abbott

Serum Institute of India Pvt. Ltd.

Sinovac Biotech Ltd

Pfizer Inc

Mylan NV

Novartis

Merck

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Analyst Market Outlook

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macro-economic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country level data:
- 3.3 Assumptions and Limitations

4. VACCINES MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis

5. VACCINES MARKET – KEY MARKET DYNAMICS

- 5.1 Vaccines Market – Key Market Dynamics
- 5.2 Market Drivers
 - 5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
 - 5.2.2 Surging Immunization Programs and Government Initiatives
- 5.3 Market Restraints
 - 5.3.1 High Vaccine Development Cost and Increased Time to Market
- 5.4 Market Opportunities
 - 5.4.1 Development of Combination and Therapeutic Vaccines
- 5.5 Future Trends
 - 5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development

5.6 Impact of Drivers and Restraints:

6. VACCINES MARKET - GLOBAL MARKET ANALYSIS

6.1 Vaccines - Global Market Overview

6.2 Vaccines - Global Market and Forecast to 2031

7. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TECHNOLOGY, 2020-2031

7.1 Overview

7.2 Live Attenuated Vaccines

7.2.1 Overview

7.2.2 Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

7.3 Inactivated Vaccines and Subunit Vaccines

7.3.1 Overview

7.3.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

7.4 Toxoid Vaccines

7.4.1 Overview

7.4.2 Toxoid Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

7.5 Conjugate Vaccines

7.5.1 Overview

7.5.2 Conjugate Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

7.6 Recombinant Vaccines

7.6.1 Overview

7.6.2 Recombinant Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

7.7 Others

8. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY DISEASE INDICATION, 2020-2031

8.1 Overview

8.2 Influenza

8.2.1 Overview

- 8.1.2 Influenza: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 8.3 Dengue
 - 8.1.1 Overview
 - 8.1.2 Dengue: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 8.4 Cytomegalovirus (CMV)
 - 8.1.1 Overview
 - 8.1.2 Cytomegalovirus (CMV): Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 8.5 Hepatitis
 - 8.1.1 Overview
 - 8.1.2 Hepatitis: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 8.6 Respiratory Syncytial Virus (RSV)
 - 8.1.1 Overview
 - 8.1.2 Respiratory Syncytial Virus (RSV): Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 8.7 Other Diseases
 - 8.1.1 Overview
 - 8.1.2 Other Diseases: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

9. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY ROUTE OF ADMINISTRATION, 2020-2031

- 9.1 Overview
- 9.2 Oral
 - 9.1.1 Overview
 - 9.1.2 Oral: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 9.3 Injectable
 - 9.1.1 Overview
 - 9.1.2 Injectable: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- 9.4 Other Route of Administration
 - 9.1.1 Overview
 - 9.1.2 Other Route of Administration: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

10. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY PATIENT TYPE, 2020-2031

- 10.1 Overview
- 10.2 Pediatric

10.2.1 Overview

10.2.2 Pediatric: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

10.3 Adult

10.3.1 Overview

10.3.2 Adult: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)

11. VACCINES MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2031 – GEOGRAPHICAL ANALYSIS

11.1 North America

11.1.1 North America Vaccines Market Overview

11.1.2 North America Vaccines Market Revenue and Forecasts to 2031

11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology

11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication

11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration

11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type

11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries

11.1.7.1 United States Vaccines Market

11.1.7.1.1 United States Vaccines Market, by Technology

11.1.7.1.2 United States Vaccines Market, by Disease Indication

11.1.7.1.3 United States Vaccines Market, by Route of Administration

11.1.7.1.4 United States Vaccines Market, by Patient Type

11.1.7.2 Canada Vaccines Market

11.1.7.2.1 Canada Vaccines Market, by Technology

11.1.7.2.2 Canada Vaccines Market, by Disease Indication

11.1.7.2.3 Canada Vaccines Market, by Route of Administration

11.1.7.2.4 Canada Vaccines Market, by Patient Type

11.1.7.3 Mexico Vaccines Market

11.1.7.3.1 Mexico Vaccines Market, by Technology

11.1.7.3.2 Mexico Vaccines Market, by Disease Indication

11.1.7.3.3 Mexico Vaccines Market, by Route of Administration

11.1.7.3.4 Mexico Vaccines Market, by Patient Type

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe

- 10.2.1 Europe Vaccines Market Overview
- 10.2.2 Europe: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
 - 10.2.2.1 Europe: Vaccines Market – Revenue and Forecast Analysis – by Technology
 - 10.2.2.2 Europe: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
 - 10.2.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
 - 10.2.2.4 Europe: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
 - 10.2.2.5 Europe: Vaccines Market – Revenue and Forecast Analysis – by Influenza
 - 10.2.2.6 Europe: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
- 10.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Country
 - 10.2.3.1 Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
 - 10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
 - 10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
 - 10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
 - 10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
 - 10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
 - 10.2.3.2 United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
 - 10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
 - 10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
 - 10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
 - 10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
 - 10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
 - 10.2.3.3 France: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
 - 10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
 - 10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
 - 10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication

10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza

10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration

10.2.3.4 Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology

10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit

Vaccines

10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication

10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza

10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration

10.2.3.5 Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology

10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit

Vaccines

10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication

10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza

10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration

10.2.3.6 Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology

10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated

Vaccines

10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication

10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza

10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration

10.3 Asia Pacific

10.3.1 Asia Pacific Vaccines Market Overview

10.3.2 Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US\$ Million)

10.3.2.1 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Technology

10.3.2.2 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines

10.3.2.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines

10.3.2.4 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication

10.3.2.5 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Influenza

10.3.2.6 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration

10.3.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Country

10.3.3.1 China: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.3.3.1.1 China: Vaccines Market Breakdown, by Technology

10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication

10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza

10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration

10.3.3.2 India: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.3.3.2.1 India: Vaccines Market Breakdown, by Technology

10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication

10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza

10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration

10.3.3.3 Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology

10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication

10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza

10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration

10.3.3.4 Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology

10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication

10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza

10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration

10.3.3.5 South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$

Million)

10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology

10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and

Subunit Vaccines

10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication

10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza

10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration

10.3.3.6 Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$

Million)

10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology

10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and

Subunit Vaccines

10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication

10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza

10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration

10.4 Middle East and Africa

10.4.1 Middle East and Africa Vaccines Market Overview

10.4.2 Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US\$ Million)

10.4.2.1 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Technology

10.4.2.2 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Live Attenuated Vaccines

10.4.2.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Inactivated Vaccines and Subunit Vaccines

10.4.2.4 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Disease Indication

10.4.2.5 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Influenza

10.4.2.6 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis –
by Route of Administration

10.4.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by
Country

10.4.3.1 South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$
Million)

10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology

10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and

Subunit Vaccines

10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication

10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza

10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration

10.4.3.2 Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology

10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and

Subunit Vaccines

10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication

10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza

10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration

10.4.3.3 United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology

10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication

10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza

10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration

10.4.3.4 Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology

10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication

10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza

10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration

10.5 South and Central America

10.5.1 South and Central America Vaccines Market Overview

10.5.2 South and Central America: Vaccines Market – Revenue, 2021–2031 (US\$ Million)

10.5.2.1 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Technology

10.5.2.2 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines

10.5.2.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines

10.5.2.4 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication

10.5.2.5 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Influenza

10.5.2.6 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration

10.5.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Country

10.5.3.1 Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology

10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication

10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza

10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration

10.5.3.2 Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology

10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication

10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza

10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration

10.5.3.3 Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology

10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines

10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines

10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication

10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza

10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration

12. INDUSTRY LANDSCAPE

12.1 Mergers and Acquisitions

12.2 Agreements, Collaborations, Joint Ventures

12.3 New Product Launches

12.4 Expansions and Other Strategic Developments

13. COMPETITIVE LANDSCAPE

13.1 Heat Map Analysis by Key Players

13.2 Ranking by Key Players

14. VACCINES MARKET - KEY COMPANY PROFILES

14.1 GlaxoSmithKline plc

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

- 14.3 Sanofi
 - 14.3.1 Key Facts
 - 14.3.2 Business Description
 - 14.3.3 Products and Services
 - 14.3.4 Financial Overview
 - 14.3.5 SWOT Analysis
 - 14.3.6 Key Developments
- 14.4 Merck and Co., Inc
 - 14.4.1 Key Facts
 - 14.4.2 Business Description
 - 14.4.3 Products and Services
 - 14.4.4 Financial Overview
 - 14.4.5 SWOT Analysis
 - 14.4.6 Key Developments
- 14.5 Serum Institute of India (SII)
 - 14.5.1 Key Facts
 - 14.5.2 Business Description
 - 14.5.3 Products and Services
 - 14.5.4 Financial Overview
 - 14.5.5 SWOT Analysis
 - 14.5.6 Key Developments
- 14.6 BioNTech
 - 14.6.1 Key Facts
 - 14.6.2 Business Description
 - 14.6.3 Products and Services
 - 14.6.4 Financial Overview
 - 14.6.5 SWOT Analysis
 - 14.6.6 Key Developments
- 14.7 Abbott
 - 14.7.1 Key Facts
 - 14.7.2 Business Description
 - 14.7.3 Products and Services
 - 14.7.4 Financial Overview
 - 14.7.5 SWOT Analysis
 - 14.7.6 Key Developments
- 14.8 Sinovac
 - 14.8.1 Key Facts
 - 14.8.2 Business Description
 - 14.8.3 Products and Services

- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 Novartis
 - 14.9.1 Key Facts
 - 14.9.2 Business Description
 - 14.9.3 Products and Services
 - 14.9.4 Financial Overview
 - 14.9.5 SWOT Analysis
 - 14.9.6 Key Developments
- 14.10 CSL Seqirus
 - 14.10.1 Key Facts
 - 14.10.2 Business Description
 - 14.10.3 Products and Services
 - 14.10.4 Financial Overview
 - 14.10.5 SWOT Analysis
 - 14.10.6 Key Developments

15. APPENDIX

- 15.1 Glossary
- 15.2 About The Insight Partners
- 15.3 Market Intelligence Cloud

List Of Tables

LIST OF TABLES

Table 1. Vaccines Market Segmentation

Table 2. Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 3. Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 4. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 5. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 6. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 7. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 8. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 9. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 10. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 11. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 12. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 13. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 14. North America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 15. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 16. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 17. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 18. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 19. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 20. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 21. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 22. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 23. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 24. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 25. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 26. United States: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 27. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 28. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 29. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 30. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 31. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 32. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 33. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 34. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 35. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 36. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 37. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 38. Canada: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 39. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 40. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 41. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 42. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 43. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 44. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 45. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 46. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 47. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 48. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 49. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 50. Mexico: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 51. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 52. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 53. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 54. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 55. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 56. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 57. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 58. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 59. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 60. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 61. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 62. Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 63. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 64. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 65. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 66. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 67. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 68. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 69. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 70. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 71. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 72. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 73. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 74. Germany: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 75. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 76. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 77. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 78. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 79. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 80. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 81. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 82. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 83. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 84. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 85. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 86. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 87. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 88. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 89. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 90. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 91. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 92. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 93. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 94. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 95. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 96. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 97. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 98. France: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 99. France: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 100. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 101. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 102. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 103. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 104. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 105. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 106. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 107. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 108. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 109. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 110. Italy: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 111. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 112. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 113. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 114. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 115. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 116. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 117. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 118. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 119. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by

Disease Indication

Table 120. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 121. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 122. Spain: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 123. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 124. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 125. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 126. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 127. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 128. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 129. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 130. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 131. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 132. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 133. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 134. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 135. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 136. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 137. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 138. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 139. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million)

– by Live Attenuated Vaccines

Table 140. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 141. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 142. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 143. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 144. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 145. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 146. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 147. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 148. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 149. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 150. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 151. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 152. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 153. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 154. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 155. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 156. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 157. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 158. China: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 159. China: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by

Route of Administration

Table 160. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 161. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 162. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 163. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 164. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 165. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 166. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 167. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 168. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 169. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 170. India: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 171. India: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 172. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 173. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 174. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 175. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 176. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 177. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 178. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 179. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by

Disease Indication

Table 180. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 181. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 182. Japan: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 183. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 184. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 185. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 186. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 187. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 188. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 189. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 190. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 191. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 192. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 193. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 194. Australia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 195. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 196. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 197. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 198. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 199. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$

Million) – by Live Attenuated Vaccines

Table 200. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 201. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 202. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 203. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 204. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 205. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 206. South Korea: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 207. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 208. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 209. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 210. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 211. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 212. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 213. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 214. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 215. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 216. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 217. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 218. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 219. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 220. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 221. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 222. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 223. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 224. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 225. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 226. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 227. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 228. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 229. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 230. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 231. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 232. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 233. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 234. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 235. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 236. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 237. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 238. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by

Disease Indication

Table 239. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 240. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 241. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 242. South Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 243. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 244. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 245. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 246. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 247. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 248. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 249. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 250. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 251. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 252. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 253. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 254. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 255. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 256. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 257. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

- Table 258. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines
- Table 259. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines
- Table 260. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines
- Table 261. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines
- Table 262. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication
- Table 263. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication
- Table 264. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza
- Table 265. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza
- Table 266. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration
- Table 267. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration
- Table 268. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology
- Table 269. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology
- Table 270. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines
- Table 271. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines
- Table 272. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines
- Table 273. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines
- Table 274. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication
- Table 275. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication
- Table 276. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza
- Table 277. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast,

2025–2031 (US\$ Million) – by Influenza

Table 278. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 279. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 280. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 281. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 282. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 283. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 284. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 285. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 286. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 287. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 288. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 289. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 290. South and Central America: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 291. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 292. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 293. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 294. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 295. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 296. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 297. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 298. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Disease Indication

Table 299. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Disease Indication

Table 300. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Influenza

Table 301. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Influenza

Table 302. Brazil: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Route of Administration

Table 303. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route of Administration

Table 304. Argentina: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Technology

Table 305. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Technology

Table 306. Argentina: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Live Attenuated Vaccines

Table 307. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Live Attenuated Vaccines

Table 308. Argentina: Vaccines Market – Revenue, 2021–2024 (US\$ Million) – by Inactivated Vaccines and Subunit Vaccines

Table 309. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Inactivated

List Of Figures

LIST OF FIGURES

- Figure 1. Vaccines Market Segmentation, by Geography
- Figure 2. PEST Analysis
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. Vaccines Market Revenue (US\$ Million), 2021–2031
- Figure 5. Vaccines Market Revenue (US\$ Million), 2021–2031
- Figure 6. Vaccines Market Share (%) – by Technology (2024 and 2031)
- Figure 7. Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 8. Livestock and Poultry: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 9. Vaccines Market Share (%) – by Disease Indication (2024 and 2031)
- Figure 10. Influenza: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 11. Medical Devices: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 12. Feed Additives: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 13. Vaccines Market Share (%) – by Route of Administration (2024 and 2031)
- Figure 14. Veterinary Hospitals: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 15. Clinics: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 16. Others: Vaccines Market – Revenue and Forecast to 2031 (US\$ Million)
- Figure 17. North America: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
- Figure 18. North America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 19. United States: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 20. Canada: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 21. Mexico: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 22. Europe: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
- Figure 23. Europe: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 24. Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 25. United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 26. France: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 27. Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

- Figure 28. Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 29. Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 30. Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
- Figure 31. Asia Pacific: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 32. China: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 33. India: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 34. Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 35. Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 36. South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 37. Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 38. Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
- Figure 39. Middle East and Africa: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 40. South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 41. Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 42. United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 43. Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 44. South and Central America: Vaccines Market – Revenue, 2021–2031 (US\$ Million)
- Figure 45. South and Central America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
- Figure 46. Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 47. Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)
- Figure 48. Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US\$ Million)

I would like to order

Product name: Vaccines Market Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others), Route of Administration (Injection, Oral, and Other), Age Group (Pediatric and Adult), and Geography

Product link: <https://marketpublishers.com/r/VEADB772E71BEN.html>

Price: US\$ 4,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VEADB772E71BEN.html>